{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"dataset_type":["N/A"],"full_dataset_link":["https://ega-archive.org/datasets/EGAD00001004387"],"sample_count":["111"],"description":["EGA dataset EGAD00001004387"],"repository":["EGA"],"title":["Ovarian Cancer Organoid Biobank"],"pubmed_abstract":["Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of OC are limited and hard to establish. We present a protocol that enables efficient derivation and long-term expansion of OC organoids. Utilizing this protocol, we have established 56 organoid lines from 32 patients, representing all main subtypes of OC. OC organoids recapitulate histological and genomic features of the pertinent lesion from which they were derived, illustrating intra- and interpatient heterogeneity, and can be genetically modified. We show that OC organoids can be used for drug-screening assays and capture different tumor subtype responses to the gold standard platinum-based chemotherapy, including acquisition of chemoresistance in recurrent disease. Finally, OC organoids can be xenografted, enabling in vivo drug-sensitivity assays. Taken together, this demonstrates their potential application for research and personalized medicine."],"pubmed_title":["An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity."],"pubmed_authors":["Kopper Oded O, de Witte Chris J CJ, Lõhmussaar Kadi K, Valle-Inclan Jose Espejo JE, Hami Nizar N, Kester Lennart L, Balgobind Anjali Vanita AV, Korving Jeroen J, Proost Natalie N, Begthel Harry H, van Wijk Lise M LM, Revilla Sonia Aristín SA, Theeuwsen Rebecca R, van de Ven Marieke M, van Roosmalen Markus J MJ, Ponsioen Bas B, Ho Victor W H VWH, Neel Benjamin G BG, Bosse Tjalling T, Gaarenstroom Katja N KN, Vrieling Harry H, Vreeswijk Maaike P G MPG, van Diest Paul J PJ, Witteveen Petronella O PO, Jonges Trudy T, Bos Johannes L JL, van Oudenaarden Alexander A, Zweemer Ronald P RP, Snippert Hugo J G HJG, Kloosterman Wigard P WP, Clevers Hans H"],"name_synonyms":["Vasp, VASP, DmelCG15112, ENHANCER OF ATNSI ACTIVITY, Data Set, MENA, NDPP1, l(2)02029, Enb, enb, ENA, Ena, CG15112, 2018., ENA/VASP"],"description_synonyms":["Product, Activity, Laboratory, ovary tumor, Platin, Tumor, dmTAF[[II]]230, Speciality, malignant tumour of ovary, Pt, ovarian cancer, diseases, mucinous, Specialities, Pharmaceutical Product, diseases and disorders, Research Activity, Laboratory Research, Priorities, OVARY NEOPL, human disease, me75, Insurance Medicine, TFIID TAF250, cel, long, D17Mit170, primary ovarian cancer, T1, NEOPL OVARIAN, Organoid, medicine, Pharmaceutical, Therapies, Medicine, Homo sapiens disease, Malignancies, stage, Ovarian Cancers, Medicines, Research Priority, Tumors, Therapy, Cancer of Ovary, Specialties, dTAF[[II]]230, TAF200, Research Priorities, TAFII-250, TAF250/230, Tl3, Tl2, Medical Specialties., Medical Speciality, TAFII250, Benign, epithelial, malignant Ovarian tumor, Diseases, Specialty, Chemotherapy, Pharmaceutic, Ovary Neoplasm, Research and Development, platine, Pharmacotherapy, platino, Heterogeneity, Benign Neoplasms, Ovary Neoplasms, study protocol, CG17603, TAF[[II]], 78Pt, ovary neoplasm, Malignant Neoplasms, experimental procedures, Activities, Insurance Medicines, disease, hyaline, Patient, Taf250, SR3-5, other neoplasm, TAF230, Ovary Cancer, other disease, d230, experimental, chemotherapy, Neoplasms, developmental stage, Benign Neoplasm, tumor of ovary, dTAFII250, neoplasm of ovary, pharmacotherapy, Pharmacotherapies, Malignant, EfW1, Chemotherapies, OVARIAN NEOPL, method, ovarian tumors, Medical Specialities, Ovarian, dmTAF1, Taf230, Genetic heterogeneity, method used in an experiment, mucous, disease or disorder, Low, Medical, Drug Therapies, TAF250, Drugs, Taf200, methods, dTAF[[II]]250, Malignancy, Research, cell, experimental section, Ovarian Cancer, Taf1p, non-neoplastic, Neoplasias, dTAF250, drugs, Platinum Black, Clients, heterogeneity, disorder, Development and Research, Preparation, Insurance, TAF, Cancer, Pharmaceuticals, WGS, Products, TAF[[II]]250, Malignant Neoplasm, cou, whole blood, ovarian neoplasm, ovary neoplasm (disease), Medical Specialty, tumor of the ovary, drug, Ovary, disorders, l(3)84Ab, medical condition, BG:DS00004.13, Ovary Cancers, Client, Cell, dTAF230, Lr, Priority, p230, Research Activities, Neoplasm, TAF[[II]]250/230, condition, TFIID, Taf[[II]]250, Cancer of the Ovary, TAF[[II]]230, Pharmaceutic Preparations, ovarian epithelial cancer, OC, TAF[II]250, patient, Cancers, Ovarian Neoplasms, ovarian tumor, plan specification, Drug, Preparations, DmelCG17603, Ovarian Neoplasm, clear, tumor of the Ovary, neoplasm of the ovary, Bra, pharmacologic therapy, Pharmaceutical Products, Neoplasia, Pharmaceutical Preparation, TAF1"],"pubmed_title_synonyms":["Ovary Cancer, Cancer of the Ovary, Cancer of Ovary, heterogeneity., ovarian neoplasm, Neoplasms, Ovarian Cancer, Ovary, ovarian epithelial cancer, OC, Ovary Neoplasms, Cancers, Ovary Cancers, primary ovarian cancer, ovary neoplasm, malignant tumour of ovary, ovarian cancer, Ovarian Neoplasm, Organoid, epithelial, Ovarian, tumor of the Ovary, malignant Ovarian tumor, Neoplasm, Ovarian Cancers, Cancer, Ovary Neoplasm"],"pubmed_abstract_synonyms":["Ovary Cancer, other disease, Product, Activity, experimental, Laboratory, chemotherapy, Neoplasms, developmental stage, Benign Neoplasm, pharmacotherapy, Platin, Pharmacotherapies, Tumor, Malignant, Chemotherapies, Speciality, malignant tumour of ovary, method, Pt, ovarian cancer, Medical Specialities, diseases, Ovarian, sensitive, Specialities, Genetic heterogeneity, method used in an experiment, Pharmaceutical Product, disease or disorder, diseases and disorders, Research Activity, Laboratory Research, Medical, Drug Therapies, sensitivity, Drugs, Priorities, human disease, methods, Insurance Medicine, Malignancy, Research, experimental section, long, Ovarian Cancer, primary ovarian cancer, non-neoplastic, Neoplasias, allergic reaction, drugs, Platinum Black, Organoid, medicine, Pharmaceutical, Clients, heterogeneity, Therapies, Medicine, disorder, Sensitivity, Homo sapiens disease, stage, Malignancies, Ovarian Cancers, Development and Research, Medicines, Preparation, Research Priority, Insurance, Cancer, Tumors, Pharmaceuticals, Therapy, Products, Cancer of Ovary, Specialties, Malignant Neoplasm, ovarian neoplasm, Medical Specialty, drug, Ovary, disorders, Research Priorities, medical condition, Ovary Cancers, Medical Specialties., Client, Medical Speciality, Priority, Benign, epithelial, malignant Ovarian tumor, Diseases, Research Activities, Neoplasm, Specialty, condition, Chemotherapy, Pharmaceutic, Ovary Neoplasm, Research and Development, Cancer of the Ovary, platine, Pharmacotherapy, platino, Pharmaceutic Preparations, Heterogeneity, Specificity, ovarian epithelial cancer, OC, Benign Neoplasms, Ovary Neoplasms, Cancers, study protocol, 78Pt, ovary neoplasm, experimental procedures, Malignant Neoplasms, plan specification, Drug, Activities, Insurance Medicines, disease, Preparations, Ovarian Neoplasm, Patient, Specificity and Sensitivity, tumor of the Ovary, pharmacologic therapy, other neoplasm, Pharmaceutical Products, Neoplasia, Pharmaceutical Preparation"],"additional_accession":[]},"is_claimable":false,"name":"ena-DATASET-UMCU-10-10-2018-09:56:24:582-1061 - samples","description":"WGS of ovarian cancer organoids, tumor samples and blood references.\nOvarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of OC are limited and hard to establish. We present a novel protocol that enables efficient derivation and long-term expansion of OC organoids. Utilizing this protocol, we have established 56 organoid lines from 32 patients, representing the spectrum of ovarian neoplasms, including non-malignant borderline tumors, as well as mucinous, clear-cell, endometrioid, low- and high-grade serous carcinomas. OC organoids recapitulate histological and genomic features of the pertinent lesion from which they were derived, illustrating intra- and inter-patient heterogeneity, and can be genetically modified.  We show that OC organoids can be used for drug screening assays and capture different tumor subtype responses to the gold standard platinum-based chemotherapy, including acquisition of chemoresistance in recurrent disease. Finally, OC organoids can be xenografted, enabling in vivo drug sensitivity assays. Taken together, this demonstrates their potential application for research and personalized medicine.","dates":{"updated":"2020-03-03 18:23:48"},"accession":"EGAD00001004387","cross_references":{"TAXONOMY":["9606"],"pubmed":["31011202"],"EGA":["EGAC00001000432","EGAS00001003073"]}}